FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
Stock Information for FSD Pharma Inc Subordinate Voting Shares
Loading
Please wait while we load your information from QuoteMedia.